Publicaciones en las que colabora con Pedro Herranz Pinto (9)

2023

  1. Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population

    Australasian Journal of Dermatology, Vol. 64, Núm. 4, pp. e317-e326

  2. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525

  3. Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)

    Dermatology and Therapy, Vol. 13, Núm. 1, pp. 329-345

2022

  1. Ustekinumab to guselkumab transitions: A series of 54 patients emulating the navigate trial in real life

    Dermatologic Therapy, Vol. 35, Núm. 10

2021

  1. Maintenance of response following discontinuation of guselkumab and secukinumab in Spanish patients who participated in the ECLIPSE study

    Journal of the European Academy of Dermatology and Venereology

2020

  1. Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Journal of the European Academy of Dermatology and Venereology, Vol. 34, Núm. 12, pp. 2821-2829

  2. The Use of Apremilast in Psoriasis: A Delphi Study

    Actas Dermo-Sifiliograficas, Vol. 111, Núm. 2, pp. 115-134

2015

  1. ¿Es útil el estudio de la inmunogenicidad en los tratamientos biológicos en psoriasis?

    Medicina Cutanea Ibero-Latino-Americana, Vol. 43, Núm. 1, pp. 10-17

2014

  1. Clinical significance of immunogenicity in biologic therapy

    Actas Dermo-Sifiliograficas, Vol. 105, Núm. 1, pp. 1-4